anhydrotetrodotoxin: sodium channel blocker; structure given in first source; from the toad Atelopus oxyrhynchus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Oxyrhynchus | genus | [no description available] | Fabaceae | The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 107878 |
MeSH ID | M0137728 |
Synonym |
---|
anhydroepitetrodotoxin |
tetrodotoxin, 4,9-dideoxy-4,9-epoxy-, (4beta,9beta)- |
anhydrotetrodotoxin |
tetrodotoxin, 4,9-anhydro- |
4-beta,9-beta-dideoxy-4,9-epoxytetrodotoxin |
4,9-anhydrotetrodotoxin |
tetrodotoxin, 4,9-dideoxy-4,9-epoxy-, (4-beta,9-beta)- |
(4-beta,9-beta)-4,9-dideoxy-4,9-epoxytetrodotoxin |
6,10-epoxy-4,8,11a-metheno-11ah-oxocino(4,3-f)(1,3,5)oxadiazepine-6,9,11-triol, 2-amino-1,4,5a,6,8,9,10,11-octahydro-9-(hydroxymethyl)-, (4s,5as,6s,8r,9s,10s,11s,11ar,12r)- |
13072-89-4 |
(2s,3s,4s,5r,11s,12s)-7-amino-2-(hydroxymethyl)-10,13,15-trioxa-6,8-diazapentacyclo[7.4.1.13,12.05,11.05,14]pentadec-7-ene-2,4,12-triol |
DTXSID301019835 |
6,10-epoxy-4,8,11a-metheno-11ah-oxocino[4,3-f][1,3,5]oxadiazepine-6,9,11-triol, 2-amino-1,4,5a,6,8,9,10,11-octahydro-9-(hydroxymethyl)-, (4s,5as,6s,8r,9s,10s,11s,11ar,12r)- |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (21.74) | 18.7374 |
1990's | 4 (17.39) | 18.2507 |
2000's | 8 (34.78) | 29.6817 |
2010's | 5 (21.74) | 24.3611 |
2020's | 1 (4.35) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.99) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (4.35%) | 6.00% |
Case Studies | 1 (4.35%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 21 (91.30%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |